![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS ADVANCES IN RADIOIMMUNOIMAGING AND RADIOIMMUNOTHERAPY
The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 December;51(4):297-303
Copyright © 2007 EDIZIONI MINERVA MEDICA
lingua: Inglese
Estimation of metastatic cure after radionuclide therapy
Bernhardt P., Forssell-Aronsson E.
Department of Radiation Physics Göteborg University, Sahlgrenska University Hospital Göteborg, Sweden
argeted radionuclide therapy of disseminated tumor disease involves many factors that will affect the therapeutic outcome. For optimization of such therapy, it is important to know how these factors affect the therapeutic outcome. In this paper, the metastatic cure probability (MCP) model is described. The MCP model is a valuable tool for analyses of the various factors influencing the metastatic cure. The factors discussed are: 1) the physical parameters (the energy and range of emitted particles, absorbed dose-distributions, and cross-irradiation of tumors from the surrounding normal tissue) and 2) the biological parameters (radiosensitivity of tumors, tumor distributions, tumor growth rate, metastasis formation rate, variable tumor activity concentration and non-homogeneous tumor activity distributions).